WBCIL Sets a Benchmark as India’s Only MSME to Win National IP Award 2024
In a proud moment for India's innovation and pharmaceutical, West Bengal Chemical Industries Limited (WBCIL) has been recognized as the only MSME in the country to secure the prestigious National Intellectual Property (IP) Award 2024 for “Excellence in Patent Filing, Grant, and Commercialization.”
- (1888PressRelease) April 04, 2025 - The award was conferred by the Ministry of Commerce & Industry, Government of India, at the renowned Bharat Mandapam, Pragati Maidan, New Delhi, in the presence of Hon’ble Minister Shri Piyush Goyal, Hon’ble Justice Pratibha M. Singh of the Delhi High Court, and prominent industry leaders.
Highlighting the significance of the occasion, Union Minister Shri Piyush Goyal remarked, “Innovation is the key to India's march towards a Viksit Bharat,” emphasizing the Government's commitment to fostering a robust intellectual property ecosystem as a driver of national progress.
The National Intellectual Property Awards, organized annually by DPIIT and the Indian IP Office, celebrate the exceptional efforts of individuals, MSMEs, corporations, and research organizations in promoting innovation through the creation and commercialization of intellectual property. This award not only honors WBCIL’s contributions but also underscores its role in uplifting India’s MSME innovation landscape.
A Legacy of Innovation and Excellence:
With a legacy spanning over six decades, WBCIL has consistently pioneered scientific advancement in APIs, fine chemicals, nutraceuticals, and liposomal technologies. Today, the company boasts 15 patents filed and 9 granted, many of which have been successfully commercialized, making a significant impact across the pharmaceutical and nutraceutical sectors. Its patents cover a range of innovations, including Ferric Carboxymaltose Iron Isomaltoside Iron (III) Coordination Complex Ferric Derisomaltose Ferric Citrate Sucroferric Oxyhydroxide Enclomiphene Citrate Improved Ferric Carboxymaltose – Designed with reduced side effects and obtained through a cost-effective process. Ferric Maltol – Development of novel polymorphic forms (‘Form S’) with a scalable and stable manufacturing process.
WBCIL's stronghold in liposomal API technology, combined with its commitment to research-led innovation, positions it at the forefront of next-generation healthcare solutions both in India and globally.
Recent Milestone: WHO-GMP & COPP Certification
Further strengthening its global footprint, WBCIL recently achieved the WHO-GMP certification and received Certificates of Pharmaceutical Product (COPP) for its key APIs:
• Ferric Ammonium Citrate B.P
• Calcium Acetate USP
• Calcium Citrate USP
• Ferrous Bisglycinate (In-House Specification)
This achievement affirms WBCIL's dedication to maintaining the highest international standards for quality, safety, and regulatory compliance — empowering it to expand its exports to highly regulated global markets.
Inspiring the Next Generation of Indian Innovators:
Commenting on the award, Mr. Sunil Kumar Agarwal, Managing Director of WBCIL, shared, “We are humbled to receive this honor as the only MSME in India recognized for patent excellence. This award reflects the collective vision, scientific rigor, and commitment of the entire WBCIL family to deliver globally competitive, patient-centric healthcare solutions.”
This accolade places WBCIL as a shining example of how Indian MSMEs, through sustained R&D, IP creation, and quality manufacturing, can compete globally and contribute to India's innovation-led growth story.
For more press releases, visit: https://www.wbcil.com/
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam